假性狂犬病抗體 | Anti-Glycoprotein H貨號Ab00772

| 代理廠牌: | ![]() |
| 原廠連結: | |
| 相關下載: |
Fc Silent™ Antibodies: Turning down the background noise
Fc Silent| 抗體 | 只要訊號不要雜訊 (Engineered Fc Domain)
Absoluted Antibody 提供一系列抗體商品,其中Fc Silent™ Antibodies系列;能有效降低非特異性Fc結合。Fc Silent™技術,為應用生物工程技術,將Fc receptors (FcγR, FcR)點突變,進而中止抗體與ADCC的功能;有效降低Fc所造成的背景訊號。Fc Silent™抗體應用於免疫細胞時flow cytometry、immunohistochemistry (IHC)資料顯示,有效降低非特異性之Fc結合,所造成的背景值。(訂購抗體前,請確認選擇抗體是否有Fc Silent™修飾標誌)
產品介紹 假性狂犬病抗體Anti-Glycoprotein H [A13-d6.3] 抗體 | 產品描述:
Description: Recombinant monoclonal antibody to Glycoprotein H. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybdridoma A13-d6.3.
UniProt Accession Number of Target Protein: A0A142I9U7
Alternative Name(s) of Target: d6.3; gH; Envelope glycoprotein H Immunogen: d6.3 was generated by immunizing mice with PrV.
Specificity: d6.3 Fab fragment binds to the core fragment of the PrV glycoprotein H (gH) ectodomain (aa 107–639) which is the membrane-proximal end of the protein in the ?gL-Pass PrV variant of PrV. The antibody contacts residues 332-373 (peripheral helices α6 and α7 of domain III of gH contribute most of the residues that form the epitope recognized by d6.3). PrV is a porcine herpesvirus belonging to the alpha-Herpesvirinae subfamily and is known to cause Aukeszky’s disease in pigs. gH is a type I membrane portein and can interact non-covalently with gL via the large gH ectodomain.
| Product Name page | Expected Species Reactivity | Applications |
| Anti-Glycoprotein H [A13-d6.3] | pseudorabies virus (PrV) | neutralize; crystalize; immunostaining |
| Anti-Rabies Virus 67kDa protein [EP5G3] | Rabies Virus | WB; NTRL; IP; ELISA |
| Anti-Rabies Virus 67kDa protein [Fab094] | Rabies Virus | WB; NTRL; ELISA; IP |
| Anti-Rabies Virus 67kDa protein [GD2D12] | Rabies Virus | WB; NTRL; IP; ELISA |
| Anti-Flavivirus group antigen [D1-4G2-4-15 (4G2)] | Dengue Virus; Zika Virus; West Nile Virus; Flaviviridae | IF; WB; NTRL; ELISA; FC |
| Anti-Ebola Nucleoprotein [KZ51] | Ebola Virus (Zaire, Ivory Coast, Reston, Sudan) | ELISA; WB; IP; IF |
| Anti-E2 A domain [F5] | Human Venezuelan Equine Encephalitis Virus | NTRL; crystallization |
| Anti-E-protein DIII (C-C’) [ZV-64] | Zika Virus | NTRL; crystallization; SPR; FC |
| Anti-dsRNA [10G1] | Virus | ELISA; IHC; WB |
| Anti-DIII domain of Dengue E protein [DV10] | Dengue Virus | ELISA; NTRL |
| Anti-DIII domain of Dengue E protein (DENV-1 and DENV-3) [DV63] | Dengue Virus | ELISA; NTRL |
| Anti-DI/DII domain of Dengue E protein [DV18] | Dengue Virus | ELISA; NTRL |
| Anti-CytomegaloVirus (CMV) gH glycoprotein [MSL-109] | CMV | NTRL |
| Anti-CPV capsid [14] | canine parovirus (CPV) | neutralize; crystallize; cryoEM |
| Anti-CMV glycoprotein gB [HCMV37] | CMV | NTRL; ELISA; IHC-Fr; IF; ICC |
| Anti-A14 [BB5.2] | Vaccinia virus | WB; IP; IF |
